ataluren (Translarna) Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.
April 2021 decisions news release Advice on four new medicines for use in conditions including multiple myeloma and severe migraine has today (Monday 12 April) been published by the Scottish Medicines Consortium. A new medicine for Duchenne Muscular Dystrophy has now also been included in the ultra-orphan pathway.
April 2016 decisions news release The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today published advice accepting three new medicines for routine use by NHSScotland.
